CAPSAICIN Trial: A Prospective Study of Capsaicin in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance or Radical Prostatectomy
试验速览
- 阶段
- 2 期
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Biomarker Changes
研究概览
简要总结
The purpose of this study is to determine the chemopreventive properties of capsaicin, the active compound in chili peppers, in prostate cancer patients enrolled in the active surveillance program or patients scheduled to undergo radical prostatectomy.
详细描述
Rationale A large body of evidence supports the role of dietary factors in prostate cancer development and progression. Most of this evidence suggests that diet high in fat including red meat and low in micronutrients and other anti-oxidants, increases the risk of disease. We are interested in the therapeutic potential of the dietary agent, capsaicin (CAP). Capsaicin is the active compound in chili peppers, and related plants. Pre-clinical studies have found that capsaicin has potent growth inhibitory and pro-apoptotic effects. It is thought that consumption of a capsaicin supplement may have a clinical benefit for subjects with localized prostate cancer who have chosen to be managed by active surveillance or improve surgical outcome of patients undergoing radical prostatectomy.
Objective(s) Primary • To assess the effect of capsaicin daily therapy on the expression of ki67 and p27 biomarkers in a post-treatment biopsy or prostate specimen from RP.
Secondary
- To assess the effect of therapy with repeat oral dosing of capsaicin two times daily on Prostate Specific Antigen (PSA) kinetics in men on active surveillance for localized prostate cancer
- To assess the effect of therapy with repeat oral dosing of capsaicin two times daily on grade and the presence of prostatic intraepithelial neoplasia (PIN) in a post-treatment biopsy
- To assess the effect of therapy with repeat oral dosing of capsaicin two times daily on the expression of markers of apoptosis, cell cycle, TRP-V1 and TRP-V6
- To assess the safety and tolerability of capsaicin therapy in men on active surveillance (AS) for prostate cancer
- To assess alterations in prostate volume and time to recurrence
Endpoint(s) Primary
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Subject is >19 years of age
- •Subject has a histologically documented diagnosis of prostate adenocarcinoma
- •Being monitored by active surveillance (see Table 1) for favourable risk prostate cancer as defined by the following:
- •Clinical stage T1b, T1c, T2a or T2b at the time of diagnosis
- •Clinical (diagnostic biopsy) Gleason score < 6
- •PSA < 10.0 ng/ml (ug/L)
- •Tumour material from most recent prostate biopsy available with sample (up to 10 unstained slides) collected for determination of ki67 and p27 biomarker expression.
- •Scheduled to have an active surveillance mandated transrectal ultrasound (TRUS) guided biopsy within 6 - 12 months of Day 1 of the study
排除标准
- •Previous malignancy (not including curatively treated basal or squamous cell carcinoma of the skin) within the previous 5 years. (Ta bladder cancer with negative surveillance cystoscopy within the past 2 years may be included.)
- •No previous or current treatment (medical therapy or radical intervention) for prostate cancer excluding biopsy
- •Inability to undergo TRUS biopsy
- •Concurrent administration of the following medications is not permitted during the protocol:
- •5 α-reductase inhibitors
- •Cytotoxic chemotherapy
- •Immunotherapy
- •Hormonal therapy (megestrol, medroxyprogesterone, cyproterone, diethylstilbestrol, hyrodcortisone, etc.)
- •Non-steroidal anti-androgens (bicalutamide, nilutamide, flutamide, etc.)
- •Luteinizing hormone releasing Hormone (LHRH) analogues (leuprolide, goserelin, etc.)
- •Ketoconazole
- •PC-SPES and any other preparations thought to have endocrine effects
- •Medications which inhibit cholesterogenesis ('statin' medications, etc.)
- •Eastern Cooperative Oncology Group (ECOG) Performance Status > 2
- •Known or history of liver disease (total bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 upper limit of normal at screening visit)
- •Subject has a minimum life expectancy of < 5 years
- •Subject is unable to give written and informed consent
结局指标
主要结局
Biomarker Changes
时间窗: 6-8 weeks or 9 +/-3 months
Determine effect of capsaicin therapy on expression of ki67 and p27 biomarkers in a post-treatment biopsy.
次要结局
- PSA Kinetics(1 year)
- Tumor grade(1 year)
- Biomarkers(1 year)
研究者
Dr. Laurence Klotz
Dr. Laurence Klotz
Sunnybrook Health Sciences Centre